Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Tax Provisions (2019 - 2025)

Historic Tax Provisions for CorMedix (CRMD) over the last 7 years, with Q3 2025 value amounting to -$56.0 million.

  • CorMedix's Tax Provisions fell 107059334.61% to -$56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.5 million, marking a year-over-year decrease of 387628.75%. This contributed to the annual value of -$1.4 million for FY2024, which is 19298.47% down from last year.
  • As of Q3 2025, CorMedix's Tax Provisions stood at -$56.0 million, which was down 107059334.61% from $521507.0 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Tax Provisions peaked at $521507.0 during Q2 2025, and registered a low of -$56.0 million during Q3 2025.
  • Moreover, its 4-year median value for Tax Provisions was -$585617.0 (2022), whereas its average is -$8.4 million.
  • Examining YoY changes over the last 5 years, CorMedix's Tax Provisions showed a top increase of 1007145.32% in 2025 and a maximum decrease of 107059334.61% in 2025.
  • Quarter analysis of 4 years shows CorMedix's Tax Provisions stood at -$1.3 million in 2021, then surged by 53.16% to -$585617.0 in 2022, then skyrocketed by 100.89% to $5230.0 in 2024, then tumbled by 1070593.35% to -$56.0 million in 2025.
  • Its last three reported values are -$56.0 million in Q3 2025, $521507.0 for Q2 2025, and $5230.0 during Q3 2024.